[HTML][HTML] Future of Acute Severe Ulcerative Colitis—A Narrative Review

L Pillay, J Selvarajah, B Andrew, B Christensen… - Journal of Clinical …, 2024 - mdpi.com
While corticosteroids have led to significant reduction in ASUC mortality over the last few
decades, they are associated with significant side effects and up to 30% of patients have …

Janus kinase inhibitors in the management of acute severe ulcerative colitis: a comprehensive review

JP Gisbert, M Chaparro - Journal of Crohn's and Colitis, 2025 - academic.oup.com
Background One third of patients with acute severe ulcerative colitis (ASUC) are steroid-
refractory. Cyclosporine and infliximab are currently the mainstays of salvage therapy. Janus …

Risk of dyslipidemia and major adverse cardiac events with tofacitinib versus adalimumab in rheumatoid arthritis: a real-world cohort study from 7580 patients

XN Ma, MF Shi, SI Wang, W Feng, SL Chen… - Frontiers in …, 2024 - frontiersin.org
Objective To compare the effects of tofacitinib and adalimumab on the risk of adverse
lipidaemia outcomes in patients with newly diagnosed rheumatoid arthritis (RA). Methods …

Navigating treatment resistance: Janus kinase inhibitors for ulcerative colitis

J Soldera - World Journal of Clinical Cases, 2024 - pmc.ncbi.nlm.nih.gov
The management of refractory ulcerative colitis (UC) and acute severe UC (ASUC) is
challenging due to the lack of standardized approaches in cases resistant to multiple …

[HTML][HTML] Defining management strategies for acute severe ulcerative colitis using predictive models: a simulation-modeling study

D Con, P De Cruz - Intestinal Research, 2024 - irjournal.org
Methods This was a simulation-based modeling study using a hypothetical cohort of 5,000
steroid-refractory ASUC patients receiving standard infliximab induction. Simulated …

[HTML][HTML] What to do when traditional rescue therapies fail in acute severe ulcerative colitis

CFDLW Suen, MC Choy, P De Cruz - Intestinal Research, 2024 - irjournal.org
Acute severe ulcerative colitis (ASUC) is a medical emergency that affects approximately
25% of patients with ulcerative colitis at some point in time in their lives. Outcomes of ASUC …

Upadacitinib in end stage renal disease: A case of acute severe ulcerative colitis

P Hilley, D Con, MC Choy, A Srinivasan… - JGH Open, 2023 - Wiley Online Library
Recent data, indicating that inflammatory bowel disease (IBD) may be a risk factor for future
chronic kidney disease, highlight the need to study the safety and clinical effectiveness of …

Acute severe ulcerative colitis: using JAK-STAT inhibitors for improved clinical outcomes

S Karthikeyan, C Ambastha… - Frontiers in …, 2024 - frontiersin.org
Acute Severe Ulcerative Colitis (ASUC) is a well-known and potentially fatal disease state,
characterized by symptoms of systemic toxicity including fever, severe anemia, elevated …

Upadacitinib as Rescue Therapy for Corticosteroid Failure Acute Severe Ulcerative Colitis: First Case Report in Asia

CS Chung, PH Le - 2024 - researchsquare.com
Background: Acute severe ulcerative colitis (ASUC) is a medical emergent condition and
approximately one-third of patients with ASUC do not respond to corticosteroid. Whether …